Skip to content
Screener

AbCellera Biologics Inc. ABCL D&A

D&A at other companies

Schrodinger logo
SchrodingerSDGR
$1.49M-2.8%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$6.41M+0.2%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$18.17M-23.8%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$12.32M-19.2%
Absci Corporation logo
Absci CorporationABSI
$2.73M-11.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.3%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046

Depreciation expense on property and equipment was $4.6 million and $6.1 million for the three months ended June 30, 2025 and 2026, respectively, and $9.0 million and $12.0 million for the six months ended June 30, 2025 and 2026, respectively.

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s D&A?
AbCellera Biologics Inc. (ABCL) reported D&A of $6.1M in Q2 2026.
How has AbCellera Biologics Inc.'s D&A changed year-over-year?
AbCellera Biologics Inc.'s D&A increased by 32.6% year-over-year, from $4.6M to $6.1M.
What is the long-term trend for AbCellera Biologics Inc.'s D&A?
Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s D&A has grown at a 42.5% compound annual growth rate (CAGR), from $4.48M to $18.49M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about AbCellera Biologics Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude